Access to new tools to combat RSV in babies likely to prove challenging
Access to new tools to combat RSV is likely to prove challenging this season, experts say.
In a fall in which new tools to fight old diseases — updated Covid-19 vaccines, new products to protect older adults and babies from RSV — have been introduced with fanfare but rolled out in a particularly rocky manner, frustration may be about to go next level.
Parents of young babies are anxiously waiting to find out how and where they’ll be able to get their children shots of Sanofi’s new monoclonal antibody that protects against RSV, or respiratory syncytial virus. People who are late in, or approaching the late stages of their pregnancies and eligible for Pfizer’s new maternal RSV vaccine — which will protect their infants after they are born — are also wondering when and where they’ll be able to get access.
What's Your Reaction?
